Nucleoside Analogs in Combination Therapy of Herpes Simplex Infections
A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or peniclovir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.
1 . A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.
2 . A method of treatment and/or prophylaxis of herpes simplex virus infections, which comprises administering to a human or animal subject, a nucleoside analogue active against herpes simplex virus, and an immunosuppressant or a pharmaceutically acceptable salt or ester thereof.
3 . The use of a nucleoside analogue antiviral active against herpes simplex virus, for the manufacture of a medicament for administration in conjunction with an immunosuppressant or a pharmaceutically acceptable salt or ester thereof, for the treatment and/or prevention of herpes simplex virus infections.
4 . A product, method, or use according to claim 1 , 2 or 3 , wherein the nucleoside analogue is acyclovir/valaciclovir or penciclovir/famciclovir.
5 . A product, method, or use according to claim 1 , 2 , 3 , or 4 , wherein the immunosuppressant is a cytotoxic agents, a corticosteroid, or a non-steroidal anti-inflammatory agent.
6 . A product, method, or use according to claim 5 wherein the immunosuppressant is cyclophosphamide, cyclosporin A, hydrocortisone, or dexamethasone.